Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Retained Earnings (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Retained Earnings for 4 consecutive years, with -$1.1 billion as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 27.66% to -$1.1 billion in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.1 billion, a 27.66% decrease, with the full-year FY2024 number at -$988.7 million, down 31.31% from a year prior.
  • Retained Earnings was -$1.1 billion for Q3 2025 at Centessa Pharmaceuticals, down from $1.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $1.6 million in Q2 2024 to a low of -$1.1 billion in Q3 2025.
  • A 4-year average of -$448.5 million and a median of -$504.8 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: skyrocketed 145.96% in 2023, then crashed 131953.42% in 2024.
  • Centessa Pharmaceuticals' Retained Earnings stood at -$1.5 million in 2022, then tumbled by 50196.93% to -$752.9 million in 2023, then plummeted by 31.31% to -$988.7 million in 2024, then decreased by 13.29% to -$1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Retained Earnings are -$1.1 billion (Q3 2025), $1.6 million (Q2 2025), and -$1.0 billion (Q1 2025).